Background In single-group studies, chromosomal rearrangements of the anaplastic lymphoma
kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an …

Background The efficacy of the ALK inhibitor crizotinib as compared with standard
chemotherapy as first-line treatment for advanced ALK-positive non–small-cell lung cancer (NSCLC) …

Background Chromosomal rearrangements of the gene encoding ROS1 proto-oncogene
receptor tyrosine kinase (ROS1) define a distinct molecular subgroup of non–small-cell lung …

Purpose Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase gene
have recently been described in a subset of non–small-cell lung cancers (NSCLCs). Because …

Background ALK gene rearrangement defines a new molecular subtype of non-small-cell
lung cancer (NSCLC). In a recent phase 1 clinical trial, the ALK tyrosine-kinase inhibitor (TKI) …

<p id="p001">Inflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neoplasm
characterized by a spindle-cell proliferation with an inflammatory infiltrate. Approximately …

Discussion Crizotinib (molecular weight, 450.34) is an anaplastic lymphoma kinase (ALK)
tyrosine kinase inhibitor (TKI) 3 that leads to responses in most patients with NSCLC …

Purpose Crizotinib is an oral kinase inhibitor approved for the treatment of ALK-rearranged
non–small-cell lung cancer (NSCLC). The clinical benefits of crizotinib in patients with brain …

Crizotinib is a dual MET and ALK inhibitor. Currently, clinical development of crizotinib is
focused primarily on ALK rearranged non-small cell lung cancer (NSCLC). Here we report an …

Purpose Amplification of the MET proto-oncogene in gastroesophageal cancer (GEC) may
constitute a molecular marker for targeted therapy. We examined a GEC cohort with follow-up …